AMPH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Amphastar Pharmaceuticals Inc (AMPH) is not a strong buy for a beginner investor with a long-term strategy at this time. The stock has mixed signals, with no immediate positive catalysts, declining financial performance, and insider selling. While the technical indicators suggest some short-term upward potential, the lack of strong growth trends and cautious analyst sentiment make it unsuitable for long-term investment right now.
The MACD is positive and expanding, indicating slight bullish momentum. However, the RSI is neutral at 45.981, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key resistance levels are at 19.87 and 20.59, while support levels are at 17.54 and 16.82. The stock closed at 19.54, slightly above the pivot of 18.705, but the overall trend remains weak.
Gross margin increased by 0.73% YoY, indicating slight operational efficiency improvement. AMP-015 and AMP-007 approvals could drive future revenue growth if executed well.
Revenue, net income, and EPS all declined significantly in the latest quarter. Insider selling has surged by over 4073.82% in the last month, signaling potential lack of confidence from management. Analysts have lowered price targets and expressed caution on pipeline execution risks.
In Q4 2025, revenue dropped by -1.83% YoY to $183.1M. Net income fell sharply by -35.65% YoY to $24.43M, and EPS declined by -29.73% YoY to 0.52. Gross margin increased slightly to 46.79%, up 0.73% YoY, but overall financial performance shows a negative trend.
Wells Fargo and BofA both lowered their price targets to $30, citing concerns about revenue guidance and pipeline execution risks. Wells Fargo maintains an Overweight rating, while BofA remains Neutral. Analysts view the stock as undervalued but are cautious about growth prospects.
